News

The multi-center study will evaluate the safety and efficacy of Portola’s compound compared to Sanofi-Aventis’ Lovenox, a current standard of care for the prevention of deep vein thrombosis

MabThera (rituximab) is already approved in the EU for first-line treatment of both aggressive and indolent non-Hodgkin’s lymphoma (NHL), in combination with chemotherapy, and as a second-line monotherapy

According to the country’s National Prescribing Service (NPS), one in four Australians incorrectly believe antibiotics can treat a common cold. This is incorrect as antibiotics work on bacteria,

The research has been published in the international peer-reviewed journal Experimental Cell Research. The paper outlines the discovery of novel genes that code for a neural regeneration peptide

AI-700, currently in phase III clinical trials, is Acusphere’s leading product candidate. The commercial scale batch, produced at the company’s commercial manufacturing facility in Tewksbury, Massachusetts, met all

The phase I study will examine whether high doses of Phytosel, INB Biotechnologies’ proprietary plant-derived oral formulation of selenium, can reduce the negative side effects of two chemotherapeutic

Effective immediately, Ricerca will begin developmental work on PhytoMedical’s BDC-03 compound for cachexia, a devastating muscle wasting condition that afflicts 25% of all AIDS patients and upwards of

The license agreement gives HepaLife exclusive rights to five issued patents. Under the terms of the agreement, HepaLife agreed to pay Michigan State University (MSU) undisclosed milestone payments

Cethrin, a recombinant protein-based inhibitor of Rho signaling, is co-delivered with a fibrin sealant and administered once directly onto the surface of the spinal cord during spinal decompression